<DOC>
	<DOCNO>NCT01075815</DOCNO>
	<brief_summary>This multicentric , open , randomize , comparative trial aim assess influence recombinant luteinizing hormone ( r-LH ) supplementation control ovarian stimulation ( COS ) advance reproductive age term improve embryo competence allow transfer less embryos avoid high grade multiple pregnancy without reduce pregnancy rate .</brief_summary>
	<brief_title>A Clinical Trial Determine Effect Lutropin Alfa Embryo Quality Implantation Rate Advanced Reproductive Age</brief_title>
	<detailed_description>This study carry Grupo de Interés de Salud Embrionaria ( GISE ) group ( part Spanish Fertility Society ) use strict criterion select embryos suitable successful transference . OBJECTIVES Primary objective : - To determine benefit r-LH supplementation COS prior in-vitro fertilization ( IVF ) /intracytosolic sperm injection ( ICSI ) advance reproductive age , term embryo competence implant , compare r-LH supplementation Secondary objective : To evaluate benefit r-LH supplementation COS , term : - follicular development - length stimulation - oocyte number maturity - fertilization rate - embryo number quality - gestational sac - abortion - ongoing pregnancy - local systemic safety r-LH administration The study consist 2 group randomize 1:1 ratio subject would follow confirmation pregnancy status . Each subject administer gonadotropin release hormone ( GnRH ) agonist subcutaneously daily previous mid luteal phase r-hCG administration standard practice achieve regulation . Each subject also administer recombinant follicle stimulate hormone ( r-FSH ) start dose 300 IU S1 ovarian stimulation completion ( r-hCG day ) part standard practice . In addition concurrent therapy , one group administer experimental treatment ( Luveris® ) group ( control group ) administer drug ( control treatment ) stimulation period stimulation start ( S1 ) ovarian stimulation completion stimulation cancellation respectively . Ovarian stimulation average take 11 day expect stimulation period extend beyond 15 day . A single injection r-hCG administer intramuscularly subcutaneously last injection Luveris r-FSH achieve final follicular maturation . After , 34-36 hour administration r-hCG OPU do oocyte retrieval embryo transfer ( ET ) conduct within 5 day OPU . Subjects also provide luteal support natural progesterone follow delivery miscarriage . Ultrasound estradiol ( E2 ) assessment follicular growth conduct various time point stimulation period without treatment adjustment .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal female subject age great ( &gt; ) 35 year Subjects baseline FSH serum level less equal ( &lt; = ) 10 IU/liter ( l ) , LH E2 level within local normal range plasma prolactin level &lt; 30 nanogram/milliliter ( ng/ml ) Subjects regular spontaneous menstrual cycle 2535 day Subjects infertility justify IVF/ICSIET treatment Subjects program COS rFSH GnRH agonist protocol Sperm current male partner suitable IVF/ICSI accord local lab , unless sperm donor foreseen Subjects presence ovary Subjects whose uterine cavity able sustain embryo implantation pregnancy Subjects normal papanicolaou test ( PAP ) smear within previous 3 year Subjects body mass index ( BMI ) &lt; 30 stimulation start Subjects receive confirmation pregnant negative betahCG test ( urine blood ) prior start rFSH administration Subjects willing able comply protocol duration study Subjects give informed consent prior studyrelated procedure part normal medical care Subjects male partner know human immunodeficiency virus , hepatitis B virus hepatitis C virus positive Subjects clinically significant systemic disease ; tumor hypothalamus pituitary gland ; ovarian , uterine mammary cancer ; hormonal abnormality and/or medical , biochemical , hematological condition judgment investigator may interfere gonadotropin treatment Subjects 2 previous assist reproductive technology ( ART ) cycle Subjects previous cycle cancel due poor response ( &lt; 3 antral follicle 15 day stimulation ) Subjects cryopreserved embryos previous ART cycle Subjects unexplained gynecological bleeding Subjects polycystic ovary , ovarian enlargement cyst unknown etiology Subjects know contraindication pregnant and/or carry pregnancy term Subjects know allergy gonadotrophin preparation excipients Subjects know active substance abuse history drug , medication alcohol abuse past 5 year Subjects previous entry study simultaneous participation another clinical drug trial Subjects refuse inability comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Ovulation induction</keyword>
	<keyword>Luveris</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Reproductive technology , assist</keyword>
</DOC>